NASDAQ:ACLX

Arcellx (ACLX) Stock Forecast, Price & News

$34.66

-1.22 (-3.40%)

(As of 05:19 PM ET)

Compare

Today's Range: $34.36
▼
$36.00
50-Day Range: $33.06
▼
$37.40
52-Week Range: $16.97
▼
$48.92

Volume: 404,535 shs
Average Volume: 497,069 shs
Market Capitalization: $1.68 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $53.42

Arcellx MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 53.8% Upside
$53.42 Price Target
Short Interest: Bearish
17.71% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.43
Based on 3 Articles This Week
Insider Trading: Selling Shares
$201,390 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.19) to ($1.87) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

669th out of 969 stocks

Biological Products, Except Diagnostic Industry

104th out of 161 stocks

3.5

Analyst's Opinion

Consensus Rating
Arcellx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $53.42, Arcellx has a forecasted upside of 53.8% from its current price of $34.73.
Amount of Analyst Coverage
Arcellx has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
17.71% of the float of Arcellx has been sold short.
Short Interest Ratio / Days to Cover
Arcellx has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Arcellx has recently decreased by 6.06%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Arcellx does not currently pay a dividend.
Dividend Growth
Arcellx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACLX.

3.6

News and Social Media Coverage

News Sentiment
Arcellx has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Arcellx this week, compared to 2 articles on an average week.
Search Interest
4 people have searched for ACLX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Arcellx to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arcellx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $201,390.00 in company stock.
Percentage Held by Insiders
Only 5.86% of the stock of Arcellx is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Arcellx are expected to grow in the coming year, from ($2.19) to ($1.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arcellx is -8.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arcellx is -8.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arcellx has a P/B Ratio of 7.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Arcellx (NASDAQ:ACLX) Stock

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

ACLX Price History

30 days | 90 days | 365 days | Advanced Chart

ACLX Stock News Headlines

October 2, 2023 | americanbankingnews.com

Arcellx, Inc. (NASDAQ:ACLX) Short Interest Down 6.1% in September

September 19, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Aclaris Therapeutics (ACRS), Incyte (INCY)

October 2, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

September 6, 2023 | seekingalpha.com

Arcellx: Clinical Hold Lifted, Charting A Brighter Path Forward (Rating Upgrade)

September 4, 2023 | finance.yahoo.com

Wall Street Analysts Believe Arcellx, Inc. (ACLX) Could Rally 35.56%: Here's is How to Trade

August 20, 2023 | finance.yahoo.com

The Arcellx, Inc. (NASDAQ:ACLX) Analysts Have Been Trimming Their Sales Forecasts

August 17, 2023 | msn.com

Baird Maintains Arcellx (ACLX) Outperform Recommendation

August 17, 2023 | finance.yahoo.com

Does Arcellx, Inc. (ACLX) Have the Potential to Rally 39.12% as Wall Street Analysts Expect?

October 2, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

August 16, 2023 | markets.businessinsider.com

Arcellx: Partial Clinical Hold Lifted By FDA On IMMagine-1 Phase 2 Trial; Q2 Net Loss Narrows

August 15, 2023 | markets.businessinsider.com

Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential

August 15, 2023 | msn.com

Needham Reiterates Arcellx (ACLX) Buy Recommendation

August 8, 2023 | benzinga.com

Arcellx Chief Medical Officer Trades $106K In Company Stock

July 31, 2023 | finance.yahoo.com

Arcellx's (NASDAQ:ACLX) investors will be pleased with their respectable 51% return over the last year

July 25, 2023 | finance.yahoo.com

Should You be Bullish on Arcellx (ACLX)?

July 6, 2023 | benzinga.com

Chief Medical Officer of Arcellx Makes $95K Sale

June 21, 2023 | seekingalpha.com

Arcellx's CAR-T Hold: Turmoil, Triumphs, And Trading Tips

June 20, 2023 | proactiveinvestors.com

Arcellx price target slashed, stock takes a hit as FDA puts hold on clinical trial following patient death

June 20, 2023 | benzinga.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX

June 20, 2023 | markets.businessinsider.com

Analyst Ratings for Arcellx

June 20, 2023 | markets.businessinsider.com

Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls

June 20, 2023 | msn.com

Why Arcellx (ACLX) Stock Is Nosediving

June 20, 2023 | finance.yahoo.com

Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death

June 20, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Arcellx Inc (ACLX)

June 20, 2023 | nasdaq.com

Arcellx : FDA Places Clinical Hold On CART-ddBCMA IND For Treatment Of R/R Multiple Myeloma

May 28, 2023 | sg.finance.yahoo.com

Arcellx, Inc. (ACLX) stock price, news, quote & history – Yahoo Finance

May 18, 2023 | msn.com

The Latest Analyst Ratings for Arcellx

See More Headlines

Receive ACLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter.

ACLX Company Calendar

Last Earnings: 8/14/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACLX
CUSIP: N/A
CIK: 1786205
Web: arcellx.com
Phone: 240-327-0603
Fax: N/A
Employees: 98
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $53.42
High Stock Price Forecast: $104.00
Low Stock Price Forecast: $39.00
Forecasted Upside/Downside: +50.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-188,680,000.00
Net Margins: N/A
Pretax Margin: -568.13%
Return on Equity: -46.20%
Return on Assets: -25.29%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 3.57
Quick Ratio: 3.57

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.68 per share
Price / Book: 7.58

Miscellaneous

Outstanding Shares: 48,360,000
Free Float: 45,525,000
Market Cap: $1.72 billion
Optionable: Not Optionable
Beta: -0.60

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Rami Elghandour (Age 44)
Chairman, CEO & Pres
Comp: $1.02M

Ms. Michelle Lim Gilson (Age 30)
Chief Financial Officer
Comp: $832.8k

Dr. Christopher R. Heery M.D. (Age 43)
Chief Medical Officer
Comp: $688.55k

Mr. Michael Dombeck M.B.A.
Chief Operating Officer

Mr. Narinderjeet Singh M.S. (Age 51)
Chief Technical Officer

Mr. David Tice Ph.D. (Age 52)
Chief Scientific Officer

Ms. Myesha Lacy
VP of Investor Relations

Ms. Maryam Abdul-Kareem J.D.
M.S., Gen. Counsel

Ms. Kate Aiken
Chief People Officer

Mr. Neeraj P. Teotia (Age 48)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACLX Stock - Frequently Asked Questions

Should I buy or sell Arcellx stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACLX shares.
View ACLX analyst ratings or view top-rated stocks.
What is Arcellx's stock price forecast for 2023?: 10 brokers have issued twelve-month price objectives for Arcellx's stock. Their ACLX share price forecasts range from $39.00 to $104.00. On average, they anticipate the company's share price to reach $53.42 in the next twelve months. This suggests a possible upside of 50.6% from the stock's current price.
View analysts price targets for ACLX or view top-rated stocks among Wall Street analysts.
How have ACLX shares performed in 2023?: Arcellx's stock was trading at $30.98 at the beginning of 2023. Since then, ACLX shares have increased by 14.5% and is now trading at $35.48.
View the best growth stocks for 2023 here.
Are investors shorting Arcellx?: Arcellx saw a decline in short interest in September. As of September 15th, there was short interest totaling 6,200,000 shares, a decline of 6.1% from the August 31st total of 6,600,000 shares. Based on an average daily trading volume, of 440,500 shares, the days-to-cover ratio is presently 14.1 days. Currently, 17.7% of the shares of the stock are short sold.
View Arcellx's Short Interest.
When is Arcellx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ACLX earnings forecast.
How were Arcellx's earnings last quarter?: Arcellx, Inc. (NASDAQ:ACLX) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.18. The business had revenue of $14.30 million for the quarter, compared to the consensus estimate of $82.38 million.

What ETFs hold Arcellx's stock?: ETFs with the largest weight of Arcellx (NASDAQ:ACLX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) and Fidelity Disruptive Medicine ETF (FMED).
When did Arcellx IPO?: (ACLX) raised $132 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 8,250,000 shares at $15.00-$17.00 per share.
What is Arcellx's stock symbol?: Arcellx trades on the NASDAQ under the ticker symbol "ACLX."
How do I buy shares of Arcellx?: Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Arcellx's stock price today?: One share of ACLX stock can currently be purchased for approximately $35.48.
How much money does Arcellx make?: Arcellx (NASDAQ:ACLX) has a market capitalization of $1.72 billion. The company earns $-188,680,000.00 in net income (profit) each year or ($3.96) on an earnings per share basis.
How can I contact Arcellx?: The official website for the company is arcellx.com. The company can be reached via phone at 240-327-0603 or via email at ir@arcellx.com.

This page (NASDAQ:ACLX) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Arcellx (ACLX) Stock Forecast, Price & News

Arcellx MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Arcellx (NASDAQ:ACLX) Stock

ACLX Price History

ACLX Stock News Headlines

ACLX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ACLX Stock - Frequently Asked Questions

Overall MarketRank^™